Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets

21st September 2017 Uncategorised 0

An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.

More: Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets
Source: News